Biocon has sold 37,65,574 equity shares of Rs.10 each of its subsidiary Syngene International through open market sale on May 16, 2018 to achieve minimum public shareholding. With this equity holding of promoter and promoter group in Syngene worked out to 72.57 per cent and public holding worked out to 25.90 per cent. Currently Syngene share is moving around Rs.605 on BSE and that of Biocon is moving around Rs.650..

For the full year ended March 2018, Biocon's consolidated net sales increased by 5.3 per cent to Rs.4,130 crore from Rs.3,922 crore in the previous year. Its other income moved up by 31.3 per cent to Rs.206 crore from Rs.157 crore. However, EBDITA declined by 8.9 per cent to Rs.1,035 crore from Rs.1,137 crore. Its net profit declined sharply by 34.2 per cent to Rs.453 crore from Rs.688 crore due to pricing pressures in generics business lower licensing income in biologics, planned shut down for plat and operating cost related to the Malaysia facility. The sales of small molecules declined by 8 per cent to Rs.1,508 crore from Rs.1,641 crore. However sales of biologics, branded formulations and research services increased by 10 per cent, 11 per cent and 19 per cent to Rs.770 crore, Rs.612 crore and Rs.1,423 crore respectively. Its net R&D expenditure touched to Rs.216 crore and gross R&D expenses reached at Rs.380 crore representing 14 per cent of operating revenue (excluding Syngene).

Similarly, for the full year ended March 2018, Syngene's standalone net sales increased by 18.5 per cent to Rs.1,423 crore from Rs.1,201 crore in the previous year. Its net profit improved by 6.2 per cent to Rs.305 crore from Rs.287 crore. Its interest cost went up by 29.3 per cent to Rs.22.7 crore from Rs.17.5 crore and other expenditure went up by 47.3 per cent to Rs.274 crore from Rs.186 crore. Forex gain worked out to Rs.73.9 crore as against Rs.22.9 crore in the previous year.